Merck’s Vorapaxar CV Outcome Follow-Up Success Not Ready To Become Standard
Executive Summary
Cardiovascular and Renal Drugs Advisory Committee says FDA should encourage lost-to-follow-up rates closer to what was seen in Merck’s TRA2P study of vorapaxar, but shouldn’t expect it.